Recro Pharma, Inc., a CDMO dedicated to solving complex formulation and manufacturing challenges for oral solid dose drugs, has signed a development and cGMP manufacturing agreement with a new client to provide early-stage development and manufacturing services to support the client’s ongoing clinical development of an orally administered, minimally-absorbed investigational compound.

“The opportunity to support our new client’s clinical development of its novel therapeutic candidate allows Recro to further highlight our unique expertise in implementing sophisticated solutions to solve complex formulation and manufacturing problems,” said David Enloe, president and chief executive officer of Recro.  “This agreement continues the momentum that we have generated by leveraging our decades-long experience in robust commercial GMP manufacturing for clinical-stage programs. We are excited to have been selected for this important work and look forward to a long and productive partnership.”